Intravitreal dexamethasone effectively reduces postoperative inflammation after vitreoretinal surgery.

Kakarla V Chalam, Sunil Malkani, Vinay A Shah

Journal: Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye 2003;34(3):188-92

PMID: 12757090

Abstract

BACKGROUND AND OBJECTIVE

Corticosteroids remain the mainstay for control of ocular inflammation after vitreous surgery. A controlled, randomized, prospective study was performed to evaluate the effectiveness of a single intravitreal injection of dexamethasone phosphate on postoperative inflammation after simple vitreous surgery in patients with proliferative diabetic retinopathy and macular pucker.

PATIENTS AND METHODS

Aqueous cell flare intensity was measured preoperatively and on days 1, 10, and 90 in 56 consecutive patients who underwent vitreous surgery for proliferative diabetic retinopathy and macular pucker. Subjects were consecutively randomized to two groups: 400 microg of intravitreal dexamethasone (treatment group) or no dexamethasone (control group)

RESULTS

Before surgery, cell and flare intensity was similar in both groups. Flare intensity was significandy lower at 10, 30, and 90 days in the proliferative diabetic retinopathy treatment group (P < .05).

CONCLUSION

Intravitreal dexamethasone significantly alleviates postoperative inflammation after vitreous surgery and is a useful adjunct.

Address: Department of Ophthalmology, University of Florida College of Medicine, Jacksonville 32209, USA.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.